CervoMed: Boral Capital Raises Buy Rating to $15 from $10 PT

CervoMed: Boral Capital Raises Buy Rating to $15 from $10 PT

CervoMed Inc. (NASDAQ:CRVO) has seen a significant upgrade in its stock rating from Boral Capital, which has increased its price target for the biotechnology company. Boral Capital has raised its rating from a "buy" to a "moderate buy" and has revised its price target from $10.00 to $15.00 per share [1].

This upgrade comes amidst a period of increased analyst interest in CervoMed, with multiple brokerages updating their coverage on the stock. Chardan Capital, for instance, increased its price target from $14.00 to $15.00 and maintained a "buy" rating [1]. Canaccord Genuity Group also raised its price target from $21.00 to $27.00, reiterating its "buy" rating [1].

Institutional investors have been actively participating in CervoMed's stock as well. Rhumbline Advisers increased its stake in the company by 35.5% in the first quarter, while other institutional investors like HighTower Advisors LLC, Bank of New York Mellon Corp, DRW Securities LLC, and Mariner LLC have also initiated new positions in the stock [1].

Despite the positive analyst sentiment, CervoMed's stock has faced some challenges. The company reported a loss of $0.70 per share in the second quarter of 2025, missing analyst estimates by 19% [2]. However, the company's revenue exceeded estimates by 22%, suggesting that while earnings have been a concern, revenue growth remains a positive indicator.

Looking ahead, CervoMed's revenue is forecast to grow at an average annual rate of 11% over the next three years, which is slightly lower than the 19% growth forecast for the US biotech industry as a whole [2]. This growth trajectory, along with the recent analyst upgrades, could provide support for CervoMed's stock price in the coming months.

References:
[1] https://www.marketbeat.com/instant-alerts/cervomed-inc-nasdaqcrvo-receives-consensus-recommendation-of-moderate-buy-from-brokerages-2025-08-04/
[2] https://finance.yahoo.com/news/cervomed-second-quarter-2025-earnings-143546613.html